ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

ATHA Athira Pharma Inc

2.245
-0.065 (-2.81%)
Last Updated: 19:29:36
Delayed by 15 minutes
Share Name Share Symbol Market Type
Athira Pharma Inc NASDAQ:ATHA NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.065 -2.81% 2.245 2.25 2.26 2.33 2.22 2.30 70,754 19:29:36

Athira Pharma to Present at H.C. Wainwright & Co. Global Life Sciences Conference

02/03/2021 12:00pm

GlobeNewswire Inc.


Athira Pharma (NASDAQ:ATHA)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Athira Pharma Charts.

Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that Leen Kawas, Ph.D., President and Chief Executive Officer, will present a corporate overview during the H.C. Wainwright & Co. Global Life Sciences Conference. A pre-recorded presentation will be available for on-demand viewing beginning at 7:00 am ET on Tuesday, March 9, 2021.

A webcast of the presentation will also be available on the Investors section of the Athira website at https://investors.athira.com/news-and-events/events-and-presentations. An archived replay of the webcast will be available for approximately 90 days following the event.

About Athira Pharma, Inc.Athira, headquartered in Seattle, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. We aim to provide rapid cognitive improvement and alter the course of neurological diseases with our novel mechanism of action. Athira is currently advancing its lead therapeutic candidate, ATH-1017, a novel small molecule for Alzheimer’s and Parkinson’s dementia. For more information, visit www.athira.com. You can also follow Athira on Facebook, LinkedIn and @athirapharma on Twitter and Instagram.

Investor & Media Contact:Julie RathbunAthira PharmaJulie.rathbun@athira.com206-769-9219

1 Year Athira Pharma Chart

1 Year Athira Pharma Chart

1 Month Athira Pharma Chart

1 Month Athira Pharma Chart

Your Recent History

Delayed Upgrade Clock